The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Combining CPX-351 and gemtuzumab ozogamicin in R/R AML and post HMA failure HR-MDS
Jayastu Senapati, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a pilot study combining CPX-351 with gemtuzumab ozogamicin in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (HR-MDS) who have failed on hypomethylating agents (HMAs). The combination showed an overall response rate (ORR) of around 30% and a composite complete response (CRc) rate of 20%, with a median overall survival (OS) of 15-18 months in patients who achieved CRc. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
